arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 2/2020 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    NEW ON THE MARKET

    Me too: rifamycin (RELAFALK) against traveller's diarrhea

    LARYNGOMEDIN OCTENIDIN ANTISEPT against sore throat

    THERAPY FROM A CRITICAL VIEWPOINT

    Stress ulcer prophylaxis with proton pump inhibitors: what's new?

    a-t READER'S QUESTIONS AND COMMENTS

    QT prolongation: is escitalopram better than citalopram?

    BEWARE MISINFORMATION

    Dasatinib (e.g. SPRYCEL): for chronic myelogenous leukaemia only the original preparation?

    IN BRIEF

    Rivaroxaban as antithrombotic therapy after transcatheter aortic-valve replacement (TAVI): more harm than benefit

    Sunscreen: benefit documented, risks of absorbed UV filters remains unclear

    CURRENT ADR NETWORK REPORT

    Severe allergic reaction with flurbiprofen lozenges (e.g. DOBENDAN DIREKT)

    SIDE EFFECTS

    Xylometazoline nasal drops – risk of incorrect dosing in infants

    Impulse control disorders with selective serotonin reuptake inhibitors (SSRIs)
    free

    Panic attacks with levonorgestrel-releasing intrauterine devices (e.g. MIRENA)

    e a-t ON THE INTERNET

    Larotrectinib (VITRAKVI) for solid tumours

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles

    Wir schätzen Ihr Feedback

    Nehmen Sie an unserer Umfrage teil!